Among the several targets, the cysteinyl leukotriene receptor 1 (CysLT1R) and the bile acid receptor GPBAR1 have been shown to be involved in disease development in several animal models of NAFLD/NASH. Here, GPBAR1 is linked to metabolic dysfunction-associated steatotic liver disease.